End-of-day quote
Other stock markets
|
||
- ILa | - |
|
07-11 | Piper Sandler Trims Price Target on Perrigo to $35 From $36, Maintains Overweight Rating | MT |
07-10 | Perrigo Divests HRA Pharma Rare Diseases Business to Esteve Healthcare | MT |
Sales 2024 * | 4.62B 1,675B 355B | Sales 2025 * | 4.83B 1,751B 371B | Capitalization | 3.69B 1,339B 283B |
---|---|---|---|---|---|
Net income 2024 * | -74M -26.83B -5.68B | Net income 2025 * | 103M 37.35B 7.91B | EV / Sales 2024 * | 1.49 x |
Net Debt 2024 * | 3.21B 1,163B 246B | Net Debt 2025 * | 3.01B 1,092B 231B | EV / Sales 2025 * | 1.39 x |
P/E ratio 2024 * |
-18.7
x | P/E ratio 2025 * |
169
x | Employees | - |
Yield 2024 * |
4.07% | Yield 2025 * |
4.33% | Free-Float | 99.66% |
Latest transcript on PERRIGO
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 29/06/23 | |
Eduardo Bezerra
DFI | Director of Finance/CFO | 49 | 15/05/22 |
Alison Ives
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Orlando Ashford
CHM | Chairman | 55 | 14/12/20 |
Jeffrey Kindler
BRD | Director/Board Member | 68 | 05/02/17 |
Bradley Alford
BRD | Director/Board Member | 67 | 05/02/17 |
1st Jan change | Capi. | |
---|---|---|
+61.53% | 848B | |
+32.89% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+13.30% | 243B | |
+16.32% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |